STEP Pharma
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2026-04-01attributed |
| Founded | unknown |
| Headquarters | Saint-Genis-Pouilly, France |
| Industry | bio |
| Stage | unknown |
| Website | step-ph.com |
STEP Pharma develops dencatistat (STP938), a first-in-class oral CTPS1 inhibitor designed to treat T-cell lymphomas, B-cell lymphomas, solid tumors, and essential thrombocythaemia. It targets oncology patients in cancers where survival has stagnated for decades, especially peripheral T-cell lymphoma. Most advanced selective CTPS1 inhibitor in clinical development.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-01 | grant | $2.7M | undisclosed |
Detected tech stack
Nginx, WordPress 7.0, Yoast SEO 27.6, Slider Revolution, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, PHP, MySQL, jquery 3.
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | step-ph.com, read 2026-05-08 |
| Description | self-reported | step-ph.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.